Saniona AB (publ) (LON:0RQJ)

Market Cap	281.86M +403.2%
Revenue (ttm)	58.68M +2,687.5%
Net Income	45.28M
EPS	0.36
Shares Out	n/a
PE Ratio	6.23
Forward PE	11.04
Dividend	n/a
Ex-Dividend Date	n/a

Volume	704
Average Volume	14,514
Open	26.38
Previous Close	25.50
Day's Range	26.30 - 26.38
52-Week Range	5.72 - 28.15
Beta	1.39
RSI	59.51
Earnings Date	Feb 26, 2026

About Saniona AB

Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company’s product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy, which is in Phase 2b clinical trial for the treatment of hypothalamic ...

• Industry: Pharmaceutical Preparations
• Founded: 2011
• Employees: 31
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RQJ

Financial Performance

Financial numbers in SEK